Financial Instruments Business Operator Kanto Finance Bureau Director (Kinsho) No. 1960 / Membership Association Investment Trusts Association, Japan Membership No. 012-02323 Go to GogoJungle Home
icon List
イチロウ
09/14/2026 02:30
Release： 09/14/2026 02:30
Update： 09/14/2026 02:30
イチロウ
Investment style : Fundamental
Investment career : 3-5 years
Investment amount : -
ICHIRO｜Financial Report Anatomy Lab I am a researcher who dissects not the surface numbers of a company, but the underlying structure and truth hidden behind them. I provide a genuine fundamentals analysis that thoroughly reads every detail of a company's financial statements (P/L, B/S, C/F, S/S) and notes, not aiming for a one-shot turnaround tool or short-term speculative trades. ■ Our Lab’s Stance 1. Complete coverage of the four financial statements We unravel the connections among the income statement (P/L), balance sheet (B/S), cash flow statement (C/F), and statement of changes in equity (S/S). 2. Extracting the anomalies and truths hidden in the notes Beyond superficial profit increases or decreases, we delve into notes and fine-grained data to visualize the structural strengths of the business model and hidden risks. 3. Fact-focused with noise eliminated We exclude vague forecasts and hype, conducting objective and logical analyses based on the confirmed facts in the financial statements. ■ Delivery and Sales Content ・Financial Statement Anatomy Reports (latest financial reports of notable companies) ・“Financial Analysis Key Points” explained from zero accounting knowledge (without using complex accounting theories, identifying the core of the financial statements and any inconsistencies) We deliver information for genuine-minded investors and business professionals who want to see the truth behind a company’s financials without requiring difficult bookkeeping knowledge.
Article cover image

【NIKE 2026 10-K Full Deconstruction Part 1】: The King’s Sudden Break — Share Buyback “93% Plummet” and $7.5 Billion Shield

ICHIRO｜Decision Report Anatomy Lab


Nike, Inc., which continues to dominate as the world's leading sports brand. Opening its latest annual report, the 2026 Form 10-K, reveals in granular detail the historic business and financial turning points the company is currently facing.

The Form 10-K's page 27 features the "PERFORMANCE GRAPH (Stock Price Performance Comparison Graph)." Here, the cumulative total return if dividends had been reinvested over the past five years is shown. Nike's stock price reached historic highs during the peak of pandemic-driven demand at home, the sneaker boom, and the Direct-to-Consumer (DTC) shift. Since then, with market expansion slowing, friction with wholesale partners as the directorship shift accelerated, and the Chinese market faltering, it has significantly underperformed the S&P 500 index.

However, what truly deserves attention is not the stock price itself, but what kind of "surgical" actions management has performed in the financial statements (B/S and C/F) behind it.

The most striking anomaly in the FY26 financial statements is that the company abruptly slowed its long-standing practice of massive "share repurchases." The program, which once allocated over $4 billion annually, has shrunk to only $12.3 million this year (a roughly 93% decrease from the previous year).

Why would the champion stop buybacks that the market would typically welcome to such an extent? We will read the reasons from the consolidated cash flow statement (page 60) and disclosures (Item 5).